Today’s post is the latest edition of my weekly recommended reads, which this week include Fate Therapeutics, COVID-19 updates, AAMC, and more including some great pubs such as one on 2 modes of PRC2 function.
I’ll start with the mid-August 2020 recommended pubs and then go to the media items, but first I wanted to highlight some good biotech news.
Mesoblast gets FDA approval for GvHD, keeps studying COVID-19
An FDA panel voted 8-2 to approve the use of Mesoblast’s remestemcel-L MSC product for acute pediatric GvHD. Based on the pre-meeting materials from the FDA some had thought Mesoblast might get bad news instead. I’m glad to see it was good news instead and hopefully this panel vote will lead to formal approval soon.
The firm is also studying the use of remestemcel-L for COVID-19 based on the idea that it might suppress cytokine storms in some patients.
We’ll have a detailed post on the Mesoblast approval in a few days.
Making Babies from Bone Marrow?
From Discover Magazine comes How Close Are We To Making Babies from Bone Marrow?
The answer is “not very”, but it’s an interesting area with many bioethical issues.
A number of groups are pursuing the idea of human reproduction from stem cells. This technology could also be used for a form of human cloning. In this case in the Discover article and others, induced pluripotent stem cells or IPSCs are the main thrust of heading toward germ cells.
Fate Therapeutics dosing it up
From my UC Davis colleagues, covered by CIRM
From STAT News, AAMC, the medical school trade association, gave $500,000 to dark-money group in 2018. I find this piece kind of unsettling even if important.